Total Payments
$58,679
2024 Payments
$21,520
Companies
10
Transactions
63
Medicare Patients
1,952
Medicare Billing
$158,470
Payment Breakdown by Category
Consulting$30,970 (52.8%)
Other$12,540 (21.4%)
Travel$11,639 (19.8%)
Food & Beverage$3,111 (5.3%)
Research$419.18 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $30,970 | 6 | 52.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,540 | 5 | 21.4% |
| Travel and Lodging | $11,639 | 15 | 19.8% |
| Food and Beverage | $3,111 | 35 | 5.3% |
| Unspecified | $419.18 | 2 | 0.7% |
Payments by Type
General
$58,260
61 transactions
Research
$419.18
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $21,978 | 13 | $0 (2017) |
| Mylan Inc. | $20,719 | 13 | $0 (2024) |
| Endo Pharmaceuticals Inc. | $8,102 | 17 | $0 (2024) |
| AbbVie, Inc. | $3,803 | 2 | $0 (2018) |
| Astellas Pharma Inc | $2,000 | 1 | $0 (2020) |
| COLOPLAST CORP | $800.88 | 6 | $0 (2024) |
| Astellas Pharma Global Development | $419.18 | 2 | $0 (2023) |
| Endo USA, Inc. | $371.97 | 3 | $0 (2024) |
| Boston Scientific Corporation | $285.43 | 2 | $0 (2023) |
| Antares Pharma, Inc. | $200.00 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,520 | 19 | Mylan Inc. ($20,719) |
| 2023 | $658.79 | 5 | Astellas Pharma Global Development ($419.18) |
| 2022 | $7,804 | 14 | Endo Pharmaceuticals Inc. ($7,527) |
| 2021 | $59.95 | 1 | Endo Pharmaceuticals Inc. ($59.95) |
| 2020 | $2,000 | 1 | Astellas Pharma Inc ($2,000) |
| 2019 | $145.82 | 1 | Boston Scientific Corporation ($145.82) |
| 2018 | $236.63 | 4 | Endo Pharmaceuticals Inc. ($183.14) |
| 2017 | $26,254 | 18 | PFIZER INC. ($21,978) |
All Payment Transactions
63 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Mylan Inc. | — | Consulting Fee | Cash or cash equivalent | $12,000.00 | General |
| 11/25/2024 | Mylan Inc. | — | Travel and Lodging | Cash or cash equivalent | $416.50 | General |
| 10/17/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $147.15 | General |
| Category: UROLOGY | ||||||
| 10/13/2024 | Mylan Inc. | VIAGRA (Drug) | Travel and Lodging | In-kind items and services | $130.00 | General |
| Category: Phosphodiesterase (PDE) inhibitors | ||||||
| 10/12/2024 | Mylan Inc. | VIAGRA (Drug) | Travel and Lodging | In-kind items and services | $189.00 | General |
| Category: Phosphodiesterase (PDE) inhibitors | ||||||
| 10/12/2024 | Mylan Inc. | VIAGRA (Drug) | Food and Beverage | In-kind items and services | $62.00 | General |
| Category: Phosphodiesterase (PDE) inhibitors | ||||||
| 10/12/2024 | Mylan Inc. | VIAGRA (Drug) | Food and Beverage | In-kind items and services | $45.00 | General |
| Category: Phosphodiesterase (PDE) inhibitors | ||||||
| 10/11/2024 | Mylan Inc. | VIAGRA (Drug) | Travel and Lodging | In-kind items and services | $189.00 | General |
| Category: Phosphodiesterase (PDE) inhibitors | ||||||
| 10/11/2024 | Mylan Inc. | VIAGRA (Drug) | Food and Beverage | In-kind items and services | $62.00 | General |
| Category: Phosphodiesterase (PDE) inhibitors | ||||||
| 10/11/2024 | Mylan Inc. | VIAGRA (Drug) | Food and Beverage | In-kind items and services | $45.00 | General |
| Category: Phosphodiesterase (PDE) inhibitors | ||||||
| 10/10/2024 | Mylan Inc. | VIAGRA (Drug) | Travel and Lodging | In-kind items and services | $189.00 | General |
| Category: Phosphodiesterase (PDE) inhibitors | ||||||
| 10/10/2024 | Mylan Inc. | — | Food and Beverage | In-kind items and services | $107.00 | General |
| 10/10/2024 | Mylan Inc. | VIAGRA (Drug) | Food and Beverage | In-kind items and services | $62.00 | General |
| Category: Phosphodiesterase (PDE) inhibitors | ||||||
| 10/09/2024 | Mylan Inc. | — | Travel and Lodging | In-kind items and services | $7,222.60 | General |
| 06/03/2024 | COLOPLAST CORP | Titan (Device) | Food and Beverage | In-kind items and services | $171.92 | General |
| Category: Men's Health | ||||||
| 05/17/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $114.61 | General |
| Category: UROLOGY | ||||||
| 05/03/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $110.21 | General |
| Category: UROLOGY | ||||||
| 05/03/2024 | COLOPLAST CORP | Titan (Device) | Food and Beverage | In-kind items and services | $103.44 | General |
| Category: Men's Health | ||||||
| 04/16/2024 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $153.20 | General |
| Category: UROLOGY | ||||||
| 12/18/2023 | Astellas Pharma Global Development | Xtandi (Drug) | — | Cash or cash equivalent | $162.35 | Research |
| Study: Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) • Category: Oncology | ||||||
| 11/17/2023 | Antares Pharma, Inc. | TLANDO (Drug), XYOSTED | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 10/25/2023 | Astellas Pharma Global Development | Xtandi (Drug) | — | Cash or cash equivalent | $256.83 | Research |
| Study: Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) • Category: Oncology | ||||||
| 09/07/2023 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $139.61 | General |
| Category: General - Erectile Dysfunction_URO | ||||||
| 04/28/2023 | Antares Pharma, Inc. | TLANDO (Drug), XYOSTED | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 12/09/2022 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $48.98 | General |
| Category: UROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | Astellas Pharma Global Development | $419.18 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 324 | 333 | $220,715 | $26,893 |
| 2022 | 4 | 529 | 547 | $325,780 | $44,695 |
| 2021 | 4 | 622 | 647 | $394,255 | $55,262 |
| 2020 | 7 | 477 | 498 | $240,230 | $31,619 |
Total Patients
1,952
Total Services
2,025
Medicare Billing
$158,470
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 141 | 149 | $91,635 | $12,248 | 13.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 104 | 104 | $97,240 | $10,279 | 10.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 48 | $20,640 | $2,770 | 13.4% |
| 93980 | Complete ultrasound of penis artery and vein blood flow | Office | 2023 | 32 | 32 | $11,200 | $1,596 | 14.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 176 | 176 | $149,140 | $20,001 | 13.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 184 | 199 | $112,565 | $15,656 | 13.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 92 | 95 | $37,125 | $5,361 | 14.4% |
| 93980 | Complete ultrasound of penis artery and vein blood flow | Office | 2022 | 77 | 77 | $26,950 | $3,678 | 13.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 227 | 227 | $191,815 | $25,901 | 13.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 220 | 240 | $135,600 | $19,715 | 14.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 92 | 96 | $37,440 | $5,427 | 14.5% |
| 93980 | Ultrasound scan of penile arterial inflow and venous outflow | Office | 2021 | 83 | 84 | $29,400 | $4,218 | 14.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 105 | 105 | $80,175 | $10,625 | 13.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 154 | 170 | $62,900 | $7,762 | 12.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 99 | 102 | $55,080 | $6,169 | 11.2% |
| 93980 | Ultrasound scan of penile arterial inflow and venous outflow | Office | 2020 | 58 | 60 | $21,000 | $3,163 | 15.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 34 | 34 | $15,810 | $2,309 | 14.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 15 | 15 | $3,075 | $1,016 | 33.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 12 | $2,190 | $575.16 | 26.3% |
About Dr. John Mulhall, MD
Dr. John Mulhall, MD is a Urology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1205813623.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Mulhall, MD has received a total of $58,679 in payments from pharmaceutical and medical device companies, with $21,520 received in 2024. These payments were reported across 63 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($30,970).
As a Medicare-enrolled provider, Mulhall has provided services to 1,952 Medicare beneficiaries, totaling 2,025 services with total Medicare billing of $158,470. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location New York, NY
- Active Since 12/28/2005
- Last Updated 04/07/2015
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1205813623
Products in Payments
- VIAGRA (Drug) $21,951
- XIAFLEX (Biological) $8,414
- Androgel (Drug) $3,803
- XTANDI (Drug) $2,000
- Titan (Device) $452.91
- Xtandi (Drug) $419.18
- TLANDO (Drug) $200.00
- TITAN (Device) $185.97
- PENILE RECONSTRUCTION (Device) $162.00
- AMS (Device) $145.82
- AVEED (Biological) $59.95
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in New York
Mr. Michael Grasso, Md, MD
Urology — Payments: $742,907
Urology $742,907
Robert Valenzuela, Md, MD
Urology — Payments: $642,070
Urology $642,070
Dr. Neil Bander, M.d, M.D
Urology — Payments: $540,525
Urology $540,525
Dr. Benjamin Brucker, Md, MD
Urology — Payments: $454,774
Urology $454,774
Katie Murray, D.o, D.O
Urology — Payments: $367,085
Urology $367,085
Dr. Ketan Badani, M.d, M.D
Urology — Payments: $308,393
Urology $308,393